<DOC>
	<DOCNO>NCT01412515</DOCNO>
	<brief_summary>Classic Kaposi 's sarcoma ( CKS ) angioproliferation associate human herpes virus 8 ( HHV8 ) , sometimes require systemic treatment . Rapamycin everolimus mTOR inhibitor . The PI3K-AKT-mTOR pathway activate CKS.The aim study evaluate rate clinical response tolerance everolimus 10mg/d CKS . Patients suffer CKS enrol multicenter two-stage phase II trial . At inclusion , patient least 10 lesion one limb 3 % body surface affect , absence symptomatic visceral CKS . The primary endpoint objective response everolimus 6 month therapy ( complete partial response per ACTG criterion ) . The trial plan use Simon 's minimax two-stage design demonstrate response rate 50 % compare 20 % type I error rate 2.5 % power 90 % . Accordingly , 11 patient enrol first stage provide least 3 patient respond , 15 patient accrued second stage .</brief_summary>
	<brief_title>A Phase II Study With Tumor Molecular Pharmacodynamic ( MPD ) Evaluation Oral mTOR-inhibitor Everolimus ( RAD001 ) 10 mg Daily Patients Suffering From Classic Endemic Kaposi 's Sarcoma</brief_title>
	<detailed_description>The primary endpoint objective response everolimus 6 month therapy ( complete partial response per ACTG criterion ) . Secondary endpoint response accord physician global assessment , lesion size , lesion infiltration , lymphedema , tolerance , pharmacodynamic ( pathologic , angiogenic lymphangiogenic biomarkers , HHV8 viral load sequential evaluation lesion , pharmacokinetic evaluation .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologic confirm classic endemic KS ( non transplant non HIV patient ) &gt; 18 Years old least 10 lesion one limb 3 % body surface affect , absence symptomatic visceral KS Presence least 4 target lesion &gt; 5mm At least 4 week wash KS specific therapy ECOG &lt; 2 immunosupressive regimen patient HIV positive creatinine clearance &lt; 40ml/mn , AST ALT &gt; 3N , neutrop√©nia &lt; 1500 , thrombopenia &lt; 150000 , anemia &lt; 8g/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>mTOR inhibitor</keyword>
</DOC>